Yi Xiaoqing, Hu Jing-Jing, Dai Jun, Lou Xiaoding, Zhao Zujin, Xia Fan, Tang Ben Zhong
Engineering Research Center of Nano-Geomaterials of Ministry of Education, Faculty of Materials Science and Chemistry, China University of Geosciences, Wuhan 430074, China.
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Key Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province, Gannan Medical University, Ganzhou 341000, China.
ACS Nano. 2021 Feb 23;15(2):3026-3037. doi: 10.1021/acsnano.0c09407. Epub 2021 Jan 15.
Nowadays, aggregation-induced emission luminogens (AIEgens) with reactive oxygen species (ROS) generating ability have been used as photosensitizers for imaging guided photodynamic therapy (PDT). To achieve enhanced antitumor outcomes, combining AIEgens-based PDT with chemotherapy is an efficient strategy. However, the therapeutic efficiency is hampered by the limited cellular uptake efficiency and the appropriate light irradiation occasion. In this paper, a self-guiding polymeric micelle (TB@PMPT) composed of two AIE photosensitizers and a reduction-sensitive paclitaxel prodrug (PTX-SS-N) was established for enhanced chemo-photodynamic therapy by a dual-stage light irradiation strategy. When the micelles were accumulated in tumor tissues, the first light irradiation (L, 6 min) was utilized to facilitate cellular uptake by "photochemical internalization" (PCI). Then, the intracellular glutathione (GSH) would induce the PTX release, micelles disassembly and the aggregation state change of AIEgens. The fluorescence signal change of two AIEgens-based ratiometric fluorescent probe could not only precisely guide the second light irradiation (L, 18 min) for sufficient ROS production, but also monitor the nonfluorescent drug PTX release in turn. Both and studies demonstrated that the dual-stage light irradiation strategy employed for TB@PMPT micelles exhibited a superior therapeutic effect over only 24 min continuous light irradiation.
如今,具有产生活性氧(ROS)能力的聚集诱导发光材料(AIEgens)已被用作成像引导光动力疗法(PDT)的光敏剂。为了实现增强的抗肿瘤效果,将基于AIEgens的光动力疗法与化疗相结合是一种有效的策略。然而,治疗效率受到有限的细胞摄取效率和合适的光照射时机的阻碍。在本文中,通过双阶段光照射策略,构建了一种由两种AIE光敏剂和一种还原敏感型紫杉醇前药(PTX-SS-N)组成的自引导聚合物胶束(TB@PMPT),用于增强化学-光动力疗法。当胶束在肿瘤组织中积累时,利用第一次光照射(L,6分钟)通过“光化学内化”(PCI)促进细胞摄取。然后,细胞内的谷胱甘肽(GSH)会诱导PTX释放、胶束解体以及AIEgens聚集状态的改变。基于两种AIEgens的比率荧光探针的荧光信号变化不仅可以精确引导第二次光照射(L,18分钟)以产生足够的ROS,还可以依次监测非荧光药物PTX的释放。体内和体外研究均表明,用于TB@PMPT胶束的双阶段光照射策略比仅24分钟的连续光照射表现出更好的治疗效果。